Navigation Links
ImmunoVaccine Technologies' DepoVax(TM) Shows Positive Results for Cancer and Infectious Diseases
Date:10/1/2008

HALIFAX, Oct. 1 /PRNewswire/ - ImmunoVaccine Technologies' (IVT) patented depot vaccine formulation, DepoVax(TM) is showing positive pre-clinical results, with single-dose efficacy achieved in therapeutic cancer and several infectious disease vaccine models. The results of this research will be presented October 4th at the Ehrlich II conference in Germany. Collaborators from the University of Miami will also be reporting on the capabilities of IVT's depot formulations for delivery of DNA and SiRNA in vivo.

DepoVax(TM) provides a unique single-dose capability, and is based on a novel approach to the use of liposomes, which encapsulate a target antigen and adjuvant. The vaccine formulation also relies on a hydrophobic oil carrier. The result is a depot effect that significantly enhances vaccine induced cell-mediated and humoral immunity.

The efficacy of a single dose of a DepoVax(TM) formulation was shown using a Human Papilloma Virus (HPV) associated cervical cancer model. In the therapeutic C3 tumor challenge model, DepoVax(TM) eliminated 100% of established cancerous tumors after a single dose. In contrast, tumors remained intact when treated with a placebo vaccine. The effect of the vaccine is linked to the activation of a potent and specific cellular immune response.

"We have developed depot vaccine formulations that can induce a more effective immune response than other vaccination strategies used in the clinic today," said Dr. Marc Mansour, vice president of R&D at IVT. "We look forward to testing our therapeutic cancer formulations in the clinic this coming year."

For the humoral response, a recombinant H5 antigen was used. IVT immunized models once with the DepoVax(TM) vaccine formulation, and once or twice with a control alum-based vaccine for avian influenza. At all time points tested, as early as 18 days and for at least 20 weeks, antibody titers induced by the depot vaccine were 10-15 times higher than a single dose of the control alum vaccine. The vaccine induced quick and strong specific immunity against the avian influenza antigen. In the longer term, the antibody responses generated were superior or equal to the two-dose alum vaccine.

"Typically, vaccines need booster shots to be effective, which is not an option in a pandemic situation," said Mansour. "Our depot vaccine formulation makes a single-dose pandemic flu vaccine a strong possibility."

IVT's strategy is multi-targeted; the company is exploring pandemic and seasonal influenza, as well as Hepatitis B. In addition, IVT is designing HLA-A2 peptide-based therapeutic depot vaccines for breast, ovarian and prostate cancers. By using tumor-specific peptides, IVT's depot vaccines induce a potent cellular response that destroys 100% of the tumors, indicating a promising immunotherapy for cancer.

About IVT

ImmunoVaccine Technologies Inc., winner of Canada's Top 10 Life Sciences Companies, is a private, clinical-stage, vaccine development company. Through its own biotech research, patented VacciMax(R) and DepoVax(TM) technologies, and collaborations with partners, IVT creates vaccines with the potential to help save and improve lives around the world. In January 2008, IVT licensed its technology to Pfizer Animal health, marking a pivotal step in achieving its vision of delivering breakthrough vaccines. http://www.immunovaccine.com


'/>"/>
SOURCE ImmunoVaccine Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
2. Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
3. Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
4. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
5. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
6. New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times
7. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
8. Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers
9. Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH)
10. Duke Licenses ALPHADAS(R), Logos Technologies EDC System to Accelerate its Early Phase Clinical Trials
11. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... MAPLE GROVE, Minn. , March 22, 2017   ... of Clomipramine Hydrochloride Capsules* USP, 25 mg, 50 mg and ... (clomipramine hydrochloride) Capsules USP. The clomipramine ... for the 12 months ending December 2016, according to IMS ... ...
(Date:3/22/2017)... 2017  Levine Cancer Institute today launched the ... to address lung cancer diagnosis, treatment and survival ... mobile lung unit is the first-of-its-kind to link ... interventions through integrated mobile technology, traditional treatment facilities ... and a lack of public transportation are barriers ...
(Date:3/22/2017)... 22, 2017  Varex Imaging Corporation (Nasdaq: ... renewed three-year pricing agreement with Toshiba Medical Systems under ... tomography (CT) tubes for integration into Toshiba Medical,s CT ... will be effective April 1, 2017. Potential ... are estimated to be in the range of $345 ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... 22, 2017 , ... Drs. Jennifer Houck, Lauren Smith, Heather Johnson and the ... in need of skilled pediatric dentistry in Rock Hill, SC, without a ... routine treatments, including cavities, sealants and fluoride applications, in a comfortable and fun environment. ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Carballo Agency, a comprehensive ... New York metropolitan region, is embarking on a cooperative charity drive with Family ... present, more than two and a half million children in the United States ...
(Date:3/22/2017)... ... 2017 , ... Schneider Insurance and Financial, a southern Montana firm providing asset ... region, is launching a charity event aimed at raising local support for Zoo Montana. ... State, and is home to a broad variety of animals from all over the ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Senior Citizens ... and prevent a default on the federal debt — including the debt held by ... growing concern, ” said TSCL in a letter to House and Senate budget leaders. ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... Sharon Kleyne ... created more than two decades ago to research evaporation of earth’s and the body’s ... promotes better health. Also the host of the nationally syndicated radio program, The Sharon ...
Breaking Medicine News(10 mins):